Durvalumab immunotherapy improved overall survival in biliary tract cancer patients when added to standard chemotherapy. September 2022, US FDA approved this combination treatment for biliary tract cancer patients in locally advanced and metastatic disease setting.
The estimated 24 month overall survival was 24.9% for durvalumab combination compared to 10.4% for the control arm. The 2 year survival data has shown improvement percentage of more than double compared to chemotherapy alone arm.
The results of this study TOPAZ-1 are published in NEJM.
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200015
The results of TOPAZ-1 are reported as significant in ASCO publication (American Society of Clinical Oncology). The addition of Immunotherapy Durvalumab showed the risk of death 20% less than those who received chemotherapy alone in Biliary Tract Cancer patients.
